Ensuring Patient Safety: Decoding FDA’s Rating System for CDMOs

To optimize manufacturing process performance and product quality, enhance supply chain reliability, and foster proactive continual improvement, the FDA’s Center for Drug Evaluation and Research (CDER) has established a program to promote quality management maturity (QMM). This program aims to encourage drug manufacturers to implement quality management practices that go beyond current good manufacturing practice (CGMP) requirements. They have developed a framework to objectively rate the Quality Management Maturity (QMM) of all pharmaceutical manufacturing sites.

Join industry experts for this important and timely webinar to take a deep dive into the program, its benefits, and the rating system.

We will explore:

• The key details of the QMM program and rating system that all drug manufacturers need to know about
• Top advantages for adherence by CDMOs
• How to overcome challenges, and what steps can be taken now to ensure success in achieving high scores
• What role this program plays in the delivery of high-quality products